Hypomethylation of the serotonin receptor type-2A Gene (HTR2A) at T102C polymorphic site in DNA derived from the saliva of patients with schizophrenia and bipolar disorder

• Published in: American journal of medical genetics. Part B, Neuropsychiatric genetics Neuropsychiatric genetics, 2011-07, Vol.156B (5), p.536-545
• Main Authors: Ghadirivasfi, Mohammad, Nohesara, Shabnam, Ahmadkhaniha, Hamid-Reza, Eskandari, Mohammad-Reza, Mostafavi, Siavash, Thiagalingam, Sam, Abdolmaleky, Hamid Mostafavi
• Format: Article
• Language: English
• Subjects: Adult and adolescent clinical studies; Alleles; Base Sequence; Biological and medical sciences; biomarker; biomarkers; Bipolar disorder; Bipolar Disorder - genetics; Bipolar Disorder - metabolism; Bipolar disorders; Bisulfite; Brain; CpG islands; CpG Islands - genetics; Cytosine; DNA - analysis; DNA Methylation; epigenetics; Gene Frequency; Genetic Predisposition to Disease; Genotype; HTR2A; Humans; Medical genetics; Medical sciences; Mental disorders; Miscellaneous; Mood disorders; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Promoters; Psychology. Psychoanalysis. Psychiatry; Psychopathology. Psychiatry; Psychoses; Receptor, Serotonin, 5-HT2A - genetics; Receptor, Serotonin, 5-HT2A - metabolism; Saliva; Saliva - metabolism; Schizophrenia; Schizophrenia - genetics; Schizophrenia - metabolism; Serotonin - metabolism; Serotonin receptors; Signal Transduction; Therapeutic applications
• ISSN: 1552-4841; 1552-485X; 1552-485X
• DOI: 10.1002/ajmg.b.31192

Several lines of evidence indicate that dysfunction of serotonin signaling and HTR2A receptor are involved in the pathogenesis of schizophrenia (SCZ) and bipolar disorder (BD). DNA methylation of HTR2A at T102C polymorphic site influences HTR2A expression and aberrant DNA methylation of HTR2A promoter was reported in postmortem brain of patients with SCZ and BD. Hypothesizing that the brain's epigenetic alteration of HTR2A may also exist in peripheral tissues that can be used as a diagnostic/therapeutic biomarker, we analyzed HTR2A promoter DNA methylation in DNA extracted from the saliva of patients with SCZ and BD, and their first degree relatives versus normal controls. Bisulfite sequencing was used to screen DNA methylation status of the HTR2A promoter CpGs and qMSP was used to quantify the degree of cytosine methylation at differentially methylated sites. Most of the cytosines of the HTR2A promoter were unmethylated. However, CpGs of the −1438A/G polymorphism site, −1420 and −1223 were >95% methylated. The CpG at T102C polymorphic site and neighboring CpGs were ∼70% methylated both in the patients and controls. qMSP analysis revealed that the cytosine of the T102C polymorphic site was significantly hypo‐methylated in SCZ, BD, and their first degree relatives compared to the controls. Cytosine methylation of HTR2A at T102C polymorphic site in DNA derived from the saliva can potentially be used as a diagnostic, prognostic, and/or therapeutic biomarker in SCZ and BD. However, these preliminary observations need to be replicated in other populations with a larger sample size to be considered for clinical applications. © 2011 Wiley‐Liss, Inc.